At ICV San Francisco 2018 at UCSF, we will host a series of presentations where change-makers and forward-thinking leaders will share their ideas and evaluate opportunities to solve some of the most complex challenges in human health.
This highly-exclusive and carefully curated event will be hosted at University of California, San Francisco (UCSF), a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. It includes top-ranked graduate schools of dentistry, medicine, nursing and pharmacy; a graduate division with nationally renowned programs in basic, biomedical, translational and population sciences; and a preeminent biomedical research enterprise. It also includes UCSF Health, which comprises two top-ranked hospitals, UCSF Medical Center and UCSF Benioff Children’s Hospital San Francisco, and other partner and affiliated hospitals and healthcare providers throughout the Bay Area.
“The doctor of the future will give no medication, but will interest his patients in the care of human frame, diet and in the cause and prevention of disease.”
– Thomas Edison
Under his leadership, UCSF Medical Center reversed what had been a $60 million annual loss in 2000 and within five years produced a $70 million annual gain. Strong financial performance has enabled the self-supporting, nonprofit medical center to pursue expansion and modernization of its facilities and equipment and make advances in quality of care, patient safety and patient satisfaction.
UC San Francisco strives to translate our scientific discoveries for public use and benefit. Whether it’s a new drug molecule, diagnostic, medical device or digital health application, the goal UCSF is to ensure the best new therapies and technologies can make their way to the patient as efficiently and safely as possible. UCSF Innovation Ventures creates new models for bringing our innovations to market by fostering entrepreneurship among our researchers and clinicians, as well as partnering with industry leaders to accelerate solutions that can directly improve health. One aim of UCSF Innovation Ventures is to keep inventions from languishing on companies’ shelves, which often occurs when firms license early-stage inventions but do not invest the necessary resources to develop them. Another is to increase the licensing revenues earned by UCSF inventions: companies are likely to pay more for innovations with more proven value.
The Center for Integrative Neuroscience was established at UC San Francisco in 1990. Within the Center, more than 80 scientists in 13 laboratories are discovering how we see and hear, how we move our limbs, why we feel pain, how we learn and remember, and how we speak and understand language. Research is focused on questions of how the nerve cells in brains work together to generate human behaviors, rather than on the operation of the nerve cells themselves. Approaches in use in the Center include the rigorous analysis of behavior, measurements of the electrical activity of individual brain cells, imaging of brain tissue with modern microscopic techniques, computer modeling, and other theoretical approaches to brain function. Research provides the foundation for applications to human neurological disease for disorders ranging from tremor to learning disabilities.
Imagine having the choice to play a video game instead of taking a drug to improve your brain health. Envision using virtual reality to reduce the need for opioids during surgery. Come explore UCSF’s Neuroscape Lab, which uses cutting-edge technologies to optimize our cognition and memory and address the challenges of ADHD, autism, and depression. Use virtual reality to fly through a human brain, and witness how a surgeon will use augmented reality to visualize a patient’s tumor in real time to remove it safely and effectively.
Helen Willsey, PhD is interested in understanding how Autism Spectrum Disorder (ASD)-associated genes function during neurodevelopment. Despite the genetic heterogeneity of ASD, several lines of evidence suggest that ASD-associated genes share common molecular underpinnings. To identify these common mechanisms, Helen leverages CRISPR/Cas9 genome editing with the diploid frog model Xenopus tropicalis. Due to the speed of frog development, Helen can rapidly study the loss of function phenotype of many ASD genes in parallel. Specifically, she injects Cas9 protein and a single guide RNA (sgRNA) against an ASD gene at the two-cell embryo stage, generating animals in which exactly half the body (separated by the midline) is mutant, allowing for direct comparison of mutant and control cells in the same animal. Helen uses a variety of techniques to identify ‘convergent phenotypes,’ including RNAseq, in situ hybridization, and immunostaining. In this way, Helen’s work is aimed at identifying phenotypes most relevant to ASD pathology to provide a path forward for understanding the molecular mechanisms underlying ASD.
A historic revolution in the longevity field is underway. Learn about the latest advances and initiatives in the aging field including a clinical trial being organized by two UCSF professors Elissa Epel and Wendy Mendez.
Nevan Krogan, PhD, thinks genomics has brought us closer to a revolution in cancer treatment than most geneticists even realize. “There’s been a tsunami of genetic data about different cancers.” But despite this rising tide of knowledge, breakthroughs in cancer treatment have been slow to materialize. In part, this is because all of the new data have only gone to show cancer’s staggering diversity: Even a single tumor can contain a unique profile of thousands of genetic mutations, leaving researchers to puzzle out which are disease drivers and which are just along for the ride. Instead of collecting yet more data, Krogan believes researchers need to look harder at the connections hidden in the data they already have. He and his colleagues think differently about where cancer comes from. Rather than see the disease as a problem caused by one or more gene mutations, they see cancer as a breakdown of large, interconnected gene networks. Different genes can malfunction in different people and still produce the same end result because of how they affect the larger networks they are part of, he says. This is why when researchers look at the cancer genomes of two people with very similar lung tumors, for instance, they may see drastically different mutation profiles.
Photo by Susan Merrell
Leading industry focused investors who leverage their talent, influence and capital to identify and grow businesses will share their investment approach and industry insights.
Championing women’s health, equality and empowerment, women leaders in healthcare will discuss health and economic empowerment, including productive resources and active participation in governance and decision-making.
“We’re in the midst of an extraordinary fight and we need every ounce of manpower we can muster, but the good news is, should we succeed, we’ll have turned the most awful paradigm that we know on it’s head… that is to say, the inevitability of death.”
– Laura Deming
Today’s cancer care looks beyond the organ in which a tumor arises by personalizing treatment to the unique genetic signature of each individual and tumor. Our cancer experts will teach you to use computational genomics sequencing techniques, which provide a road map for personal cancer treatment and prevention plans. Witness a live molecular tumor board and the multidisciplinary brain power engaged in solving the most complex cancer patient cases.
The University of California at San Francisco Laboratory for Orthopaedic Bioengineering is directed by Jeffrey C. Lotz, Ph.D. The laboratory is located within the Department of Orthopaedic Surgery and aims to understand the biomechanics and biology of the lumbar spine and intervertebral disc in both health and disease. A number of research programs in this area include: theoretical and experimental development of material laws for disc tissues; finite element simulations of disc and vertebral body response to in vivo loading; animal models to clarify the mechanisms of disc degeneration and repair; animal models to clarify the relationship between disc degeneration and pain; investigation of novel surgical interventions meant to treat back pain; and tissue engineering of fibro-cartilaginous tissues.
The fountain of youth can be found in a UCSF lab, where researchers are exploring the biology of aging. From muscle to blood to neurons, scientists are finding the keys to understanding and ultimately reversing aging. Learn and experiment with the innovative scientists who explore how exercise reverses muscle aging, how women can better predict their reproductive age, and how factors in our bodies can be directed to preserve our brains.
Business leaders of emerging growth companies share how they are tackling some of the most complex challenges in human health.
Discussion: How to Ensure Innovative Technologies Improve Efficacy and Quality of Cancer Care
Taking a medical device from concept to clinic: What entrepreneurs, biotech Investors, and inventers need to keep in mind.
UCSF: The Campaign launches with a goal to raise $5B to tackle the grand challenges.
Your Donations Make a Difference.
Care, heal, teach, discover: That’s what your gifts empower UCSF to do. Your generosity keeps UCSF nimble and innovative, able to take on urgent challenges and promising opportunities.
UCSF Medical Center at Mission Bay
William J. Rutter Center
Fisher Banquet Hall
Address: 1675 Owens Street, San Francisco, CA 94158
Phone: (415) 353-3000
Mission Bay is home to UCSF Benioff Children’s Hospital San Francisco, UCSF Betty Irene Moore Women’s Hospital and UCSF Bakar Cancer Hospital, in addition to numerous outpatient services for both children and adults.
|09:00 AM||Registration & Breakfast|
Fisher Banquet Hall
|09:25||9:30||Welcome Remarks: Joe Krovoza, JD, Director of Development for Cancer Programs|
|09:30||10:15||Neuroscience of Depression | Addiction: Vikaas Sohal, MD, PhD, Josh Berke, PhD, Danielle Ramo, PhD, Shawn Singh of Vistagen Therapeutics, Andrew Krystal, MD|
|10:20||10:40||Investing in Innovation from an Institutional Perspective: Gary Magnant of ICV, Steve Massocca of Wedbush, Eric Rice of Wellington Management, Robert Smith of ICV, Dr. Joon Yun of Palo Alto Investors|
|11:00||11:30||New Pathways for Neurology: Autism and the Brain: Helen Willsey, PhD|
|11:30||12:00||Virtual Reality, Real Science: Joaquin Anguera, PhD|
|12:00||1:30||Networking Luncheon | Speaker Presentations|
|12:15||12:30||Big Ideas to Market: Barry Selick, MD and Thomas Quinlan of Reed Smith|
|12:30||12:50||Leadership Spotlight: Mark Laret, President and CEO of UCSF Health and Jim Burness|
|12:50||1:10||Future of Functional Longevity: Dr. Joon Yun, President of Palo Alto Investors|
|1:30||2:15||Women Leaders in Healthcare: Laura Deming of The Longevity Fund, Julia Gregory of Isometry Advisors, Deepa Pakianathan, PhD of Delphi Ventures, Cami Samuels of Venrock|
|2:20||3:05||Innovative Cancer Treatment: Eric Collisson, MD, Larry Fong, MD, Mark Moasser, MD and Nelson Teng, MD|
|3:10||3:25||Orthopedic Bioengineering: Jeffrey Lotz, PhD|
|3:25||3:40||Regenerative Medicine: Stem Cells: Sarah Knox, PhD|
|3:45||4:00||Using Big Data to Uncover the Hidden Genetic Network of Disease: Nevan Krogan, PhD|
|4:00||4:30||CEO Roundtable: Neotherma Oncology, Michael Wandell & Nexeon Medsystems, Daniel Powell|
|4:30||4:40||Closing Remarks: Robert Smith, Founder of ICV|
|4:40||6:00||Networking Reception||COMPANY PRESENTATION|